Anti-CD20 mAbs were originally created to treat B cell proliferative diseases such as non-Hodgkin's lymphoma and chronic ...

Human therapeutic antibodies constitute the industry’s fastest-growing therapeutic class. In the US, more than 500 antibodies are in various stages of clinical development, and the number of ...

Stanford scientists discovered that a harmless skin bacterium triggers a powerful immune response. By tweaking a bacterial ...

A study published in December by Duke professor Rohit Singh and his team proposes a new computational model called antibody ...

Recombinant antibodies are invented antibodies formed by using recombinant DNA technology. While traditional monoclonal antibodies are derived from hybridoma technology, the recombinant antibodies are ...

Nevertheless, the team believes these engineered antibody candidates could aid in developing effective human-derived antivenom against Latrodectus species, weaving a new web of hope for black widow ...

View Full Profile. Learn about our Editorial Policies. For decades, researchers fixated on the extraordinary potential nestled within the human immune system, particularly the formidable prowess of ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Learn how analytical methodologies can be used to identify RSV pre- and post-fusion proteins for vaccine development.

Researchers have a new hope for preventing severe illness from the bird flu after finding a groundbreaking antibody treatment ...

Inhalon’s inhaled antibody therapy aims to address this need, the release said. Its RSV candidate is part of a more broad effort to develop therapies that deliver therapeutic antibodies directly to ...